Oramed Pharmaceuticals Inc. (ORMP: Quote) announced that the FDA has cleared the company's Investigational New Drug application for ORMD-0801, its oral insulin capsule.
Oramed's ORMD-0801 is an orally ingestible insulin capsule indicated for the early stages of type 2 diabetes, when it can still slow the rate of degeneration of the disease by providing additional insulin to the body and allowing pancreatic respite.
Click here to receive FREE breaking news email alerts for Oramed Pharmaceuticals Inc. and others in your portfolio
by RTT Staff Writer
For comments and feedback: email@example.com